Related Experiment Video
Updated: Feb 12, 2026

An Organotypic High Throughput System for Characterization of Drug Sensitivity of Primary Multiple Myeloma Cells
Published on: July 15, 2015
Microfluidic enrichment of plasma cells improves treatment of multiple myeloma
Yunjing Zeng1,2, Li Gao1,2, Xiaoqing Luo2
1Division of Periodontology, Diagnostic Sciences & Dental Hygiene, Division of Biomedical Sciences, Herman Ostrow School of Dentistry, University of Southern California, Los Angeles, CA, USA.
Abstract:
Cytogenetic alterations form the basis for risk stratification for multiple myeloma (MM) and guide the selection of therapy; however, current pathology assays performed on bone marrow samples can produce false-negatives due to the unpredictable distribution and rarity of MM cells. Here, we report on a microfluidic device used to facilitate CD45 depletion to enhance the detection of cytogenetic alterations in plasma cells (PCs). Bone marrow samples from 48 patients with MM were each divided into two aliquots. One aliquot was subjected to classic flow cytometry and fluorescent in situ hybridization (FISH). The other first went through CD45+ cell depletion, further enriched by microfluidic size selection. The enriched samples were then analyzed using flow cytometry and FISH and compared to those analyzed using the classic method only. Unlike the traditional method, the microfluidic device removed the CD45+ leukocytes and specifically selected PCs from the remaining white blood cells. Therefore, the microfluidic method (MF-CD45-TACs) significantly increased the percentage of CD38+ /CD138+ cells to 37.7 ± 20.4% (P < 0.001) from 10.3 ± 8.5% in bone marrow. After the MF-CD45-TAC enrichment, the detection rate of IgH rearrangement, del(13q14), del(17p), and 1q21 gains, rose to 56.3% (P < 0.001), 37.5% (P < 0.001), 22.9% (P < 0.001), and 41.7% (P = 0.001), respectively; all rates of detection were significantly increased compared to the classically analyzed samples. In this clinical trial, this microfluidic-assisted assay provided a precise detection of cytogenetic alterations in PCs and improved clinical outcomes.
Insights
A novel microfluidic device enhances multiple myeloma (MM) diagnosis by improving the detection of critical cytogenetic alterations in plasma cells (PCs). This method increases diagnostic accuracy and aids in better patient risk stratification and treatment selection.
Area of Science:
- Hematology
- Biotechnology
- Medical Diagnostics
Background:
- Cytogenetic alterations are crucial for multiple myeloma (MM) risk stratification and therapy selection.
- Conventional pathology assays on bone marrow samples can yield false-negatives due to rare or unevenly distributed MM cells.
- Accurate detection of genetic abnormalities in plasma cells (PCs) is essential for effective MM management.
Purpose of the Study:
- To develop and evaluate a microfluidic device for CD45 depletion and PC enrichment to improve cytogenetic analysis in MM.
- To enhance the sensitivity and accuracy of detecting cytogenetic alterations in MM plasma cells.
- To assess the clinical utility of microfluidic-assisted CD45 depletion for MM diagnosis.
Main Methods:
- A microfluidic device was used for CD45+ leukocyte depletion and size-based plasma cell (PC) selection from bone marrow samples of 48 MM patients.
- Enriched PCs were analyzed using flow cytometry and fluorescence in situ hybridization (FISH).
- Results were compared to conventional flow cytometry and FISH analysis without enrichment.
Main Results:
- The microfluidic method (MF-CD45-TACs) significantly increased the percentage of CD38+/CD138+ cells (37.7% vs. 10.3%, P < 0.001).
- Detection rates for IgH rearrangement, del(13q14), del(17p), and 1q21 gains were significantly increased post-enrichment (e.g., IgH rearrangement: 56.3%, P < 0.001).
- The microfluidic assay demonstrated significantly higher detection rates for key cytogenetic alterations compared to the classic method.
Conclusions:
- Microfluidic-assisted CD45 depletion and PC enrichment improve the detection of cytogenetic alterations in multiple myeloma.
- This technology offers a more precise diagnostic tool for MM, potentially leading to improved clinical outcomes.
- The MF-CD45-TACs assay represents a significant advancement in the pathological analysis of multiple myeloma.
Related Concept Videos
Multiple Allele Traits
Protein Buffers in Blood Plasma and Cells
Certain amino acids can exist in a zwitterion state at a...
Multiple Regression
Farmers can use multiple regression to determine the crop yield based on more than one factor, such as water availability, fertilizer, soil properties, etc. Here, the crop yield is the response or dependent variable as it depends on the other independent variables. The analysis requires the construction of a scatter plot...
Composition of Blood Plasma
Improving Translational Accuracy
Improving Translational Accuracy

